亚临床银屑病关节炎与疾病拦截——2024年进展
本文综述亚临床银屑病关节炎(PsA)的命名体系、危险因素及疾病拦截潜力。EULAR命名提出从银屑病到临床PsA的三个阶段:PsA风险期、亚临床PsA和早期PsA。近期回顾性观察研究显示,使用生物改善病情抗风湿药治疗银屑病可能预防PsA出现,但部分研究显示TNF抑制剂未降低PsA发生率,亟需进一步数据。
要点
- EULAR命名将银屑病到临床PsA分为三个阶段:PsA风险期、亚临床PsA和早期PsA。
- 近期回顾性观察研究显示,生物改善病情抗风湿药治疗银屑病可能拦截PsA发生。
- 部分研究中TNF抑制剂治疗银屑病未降低PsA发生率,需进一步数据。
核心结论
- 近期回顾性观察研究显示疾病拦截可行,即治疗银屑病患者可能预防PsA出现,尤其使用生物改善病情抗风湿药。
- 由于部分研究中TNF抑制剂治疗银屑病未降低PsA发生率这一意外发现,亟需进一步数据。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- EULAR命名提出从银屑病到临床PsA的简化三阶段:PsA风险期、亚临床PsA和早期PsA。
- 近期回顾性观察研究显示疾病拦截可行,即治疗银屑病患者可能预防PsA出现,尤其使用生物改善病情抗风湿药。
- 部分研究中TNF抑制剂治疗银屑病未降低PsA发生率。
关键数值与推荐
- EULAR命名提出从银屑病到临床PsA的简化三阶段:PsA风险期、亚临床PsA和早期PsA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分研究中TNF抑制剂治疗银屑病未降低PsA发生率,这一意外发现提示亟需进一步数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriatic arthritis (PsA) is a chronic rheumatic disease that usually appears in patients with skin psoriasis, making it a model for detection of joint disease in the pre-clinical phases in a setting where therapy for cutaneous disease may ameliorate or prevent arthritis development. Such PsA prevention appears credible due to the increasingly recognized closely shared immunopathology between the skin and joints, especially the entheses. Recently, several initiatives have explored the concept of pre-clinical PsA, and nomenclatures have been developed with the recent EULAR nomenclature proposing a simplified three stages from psoriasis to clinical PsA development, namely at risk of PsA, subclinical PsA and early PsA. A better comprehension of early PsA and the identification of individuals predisposed to its development could enable interventions to 'prevent' the appearance of PsA. Several recent retrospective observational studies have demonstrated disease interception feasibility, i.e. treatment of people with psoriasis may prevent the appearance of PsA, in particular using biologic disease-modifying drugs. However, further data are urgently required due to unexpected findings in some studies where TNF inhibition for psoriasis does not reduce the rate of PsA development. In this review we address the current challenges in early PsA, including comparisons of pre-PsA nomenclature sets, its risk factors and the potential for disease interception.
引用
- López-Medina C, McGonagle D, Gossec L, et al. Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 2025. PMID: 39150442. doi:10.1093/rheumatology/keae399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。